Hyponatremia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hyponatremia. 16 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
16
Active US patents
36/100
Avg vulnerability
$1.2B
Annual revenue covered

Originators in Hyponatremia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Otsuka 16 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hyponatremia. Each bar = one year. Y-axis scaled to peak year (8 patents).

8
26
8
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Samsca
TOLVAPTAN
 Otsuka 16 36 $1.2B 2026-09-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07
8501730 Samsca composition of matter 27 2026-09-01
8501730 Samsca composition of matter 27 2026-09-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8501730 Samsca composition of matter 22 2026-09-01
8501730 Samsca composition of matter 22 2026-09-01
8501730 Samsca composition of matter 22 2026-09-01
8501730 Samsca composition of matter 22 2026-09-01
8501730 Samsca composition of matter 22 2026-09-01
8501730 Samsca composition of matter 27 2026-09-01
8501730 Samsca composition of matter 27 2026-09-01
8501730 Samsca composition of matter 27 2026-09-01
10905694 Samsca formulation 48 2030-04-07
10905694 Samsca formulation 48 2030-04-07

Related